↓ Skip to main content

Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma

Overview of attention for article published in Frontiers in oncology, August 2019
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (66th percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

twitter
5 X users
patent
3 patents

Citations

dimensions_citation
106 Dimensions

Readers on

mendeley
75 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma
Published in
Frontiers in oncology, August 2019
DOI 10.3389/fonc.2019.00767
Pubmed ID
Authors

Yaqing Cao, Wenyi Lu, Rui Sun, Xin Jin, Lin Cheng, Xiaoyuan He, Luqiao Wang, Ting Yuan, Cuicui Lyu, Mingfeng Zhao

X Demographics

X Demographics

The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 75 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 75 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 15%
Student > Bachelor 9 12%
Researcher 7 9%
Student > Master 7 9%
Other 6 8%
Other 11 15%
Unknown 24 32%
Readers by discipline Count As %
Medicine and Dentistry 20 27%
Immunology and Microbiology 9 12%
Biochemistry, Genetics and Molecular Biology 7 9%
Agricultural and Biological Sciences 4 5%
Pharmacology, Toxicology and Pharmaceutical Science 3 4%
Other 4 5%
Unknown 28 37%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 06 October 2022.
All research outputs
#7,051,839
of 25,385,509 outputs
Outputs from Frontiers in oncology
#2,370
of 22,432 outputs
Outputs of similar age
#116,891
of 352,137 outputs
Outputs of similar age from Frontiers in oncology
#60
of 341 outputs
Altmetric has tracked 25,385,509 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 22,432 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 352,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 341 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 81% of its contemporaries.